This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Susan R. Heckbert, MD, PhD; Noel S. Weiss, MD, DrPH; Thomas D. Koepsell, MD, MPH; Rozenn N. Lemaitre, PhD, MPH; Nicholas L. Smith, MPH; David S. Siscovick, MD, MPH; Danyu Lin, PhD; Bruce M. Psaty, MD, PhD

Arch Intern Med. 1997;157(12):1330-1336.

Abstract
Background
There is little information about whether an increasing duration of estrogen replacement therapy is associated with a declining risk for myocardial infarction in postmenopausal women.

Objective
To conduct a population-based, case-control study among enrollees of the Group Health Cooperative (GHC) of Puget Sound, Seattle, Wash.

Subjects and Methods
Case subjects were all post-menopausal women who were enrolled in the GHC with an incident fatal or nonfatal myocardial infarction from July 1986 through December 1993. Control subjects were a stratified random sample of postmenopausal women who were enrolled in the GHC without myocardial infarction and matched to case subjects by age and calendar year. We reviewed the medical records of the 850 case subjects and 1974 control subjects and conducted telephone interviews with consenting survivors. Use of estrogen or estrogen and progestin was assessed using GHC's computerized pharmacy database.

Results
Among women who were currently using estrogen, a longer duration of use was inversely associated with a risk for myocardial infarction after adjustment for age, year of identification, diabetes mellitus, angina, and smoking. For categories of increasing duration of estrogen use (never, >0-<1.8 years, 1.8-<4.2 years, 4.2-<8.2 years, and 8.2 years), the odds ratios for myocardial infarction were 1.00 (reference), 0.91, 0.70, 0.65, and 0.55 (for trend among the current users, P=.05). Among women who had used estrogen in the past, there was no evidence of decreasing risk with increasing duration of estrogen use.

Conclusion
In this study, a long duration of hormone replacement therapy among women currently using estrogen was associated with a reduced risk for first myocardial infarction.

Arch Intern Med. 1997;157:1330-1336

Author Affiliations
From the Departments of Epidemiology (Drs Heckbert, Weiss, Koepsell, Smith, Siscovick, and Psaty), Medicine (Drs Koepsell, Lemaitre, Siscovick, and Psaty), Biostatistics (Dr Lin), and Health Services (Drs Koepsell and Psaty), Cardiovascular Health Research Unit, University of Washington, Seattle.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Postmenopausal Hormone Therapy and Risk of Cardiovascular Disease by Age and Years Since Menopause
Rossouw et al.
JAMA 2007;297:1465-1477.
ABSTRACT | FULL TEXT  

Conjugated Equine Estrogen, Esterified Estrogen, Prothrombotic Variants, and the Risk of Venous Thrombosis in Postmenopausal Women
Smith et al.
Arterioscler. Thromb. Vasc. Bio. 2006;26:2807-2812.
ABSTRACT | FULL TEXT  

Risk of New-Onset Atrial Fibrillation in Relation to Body Mass Index
Dublin et al.
Arch Intern Med 2006;166:2322-2328.
ABSTRACT | FULL TEXT  

Hormone Replacement Therapy and the Cardiovascular System: Lessons Learned and Unanswered Questions
Ouyang et al.
J Am Coll Cardiol 2006;47:1741-1753.
ABSTRACT | FULL TEXT  

The effect of tibolone and continuous combined conjugated equine oestrogens plus medroxyprogesterone acetate on progression of carotid intima-media thickness: the Osteoporosis Prevention and Arterial effects of tiboLone (OPAL) study
Bots et al.
Eur Heart J 2006;27:746-755.
ABSTRACT | FULL TEXT  

Esterified estrogen and conjugated equine estrogen and the risk of incident myocardial infarction and stroke.
Lemaitre et al.
Arch Intern Med 2006;166:399-404.
ABSTRACT | FULL TEXT  

Progesterone Antagonizes the Vasoprotective Effect of Estrogen on Antioxidant Enzyme Expression and Function
Wassmann et al.
Circ. Res. 2005;97:1046-1054.
ABSTRACT | FULL TEXT  

Acupuncture-Point Stimulation for Chemotherapy-Induced Nausea and Vomiting
Ezzo et al.
JCO 2005;23:7188-7198.
ABSTRACT | FULL TEXT  

Combined Postmenopausal Hormone Therapy and Cardiovascular Disease: Toward Resolving the Discrepancy between Observational Studies and the Women's Health Initiative Clinical Trial
Prentice et al.
Am J Epidemiol 2005;162:404-414.
ABSTRACT | FULL TEXT  

Vascular consequences of menopause and hormone therapy: Importance of timing of treatment and type of estrogen
Dubey et al.
Cardiovasc Res 2005;66:295-306.
ABSTRACT | FULL TEXT  

Esterified Estrogens and Conjugated Equine Estrogens and the Risk of Venous Thrombosis
Smith et al.
JAMA 2004;292:1581-1587.
ABSTRACT | FULL TEXT  

Sex-specific differences in ventricular expression and function of parathyroid hormone-related peptide
Grohe et al.
Cardiovasc Res 2004;61:307-316.
ABSTRACT | FULL TEXT  

Issues to debate on the Women's Health Initiative (WHI) study: Hormone replacement therapy and acute coronary outcomes: methodological issues between randomized and observational studies
Garbe and Suissa
Hum Reprod 2004;19:8-13.
ABSTRACT | FULL TEXT  

Estrogen Therapy and Risk of Cardiovascular Events Among Women With Type 2 Diabetes
Newton et al.
Diabetes Care 2003;26:2810-2816.
ABSTRACT | FULL TEXT  

Attenuated Responses to Angiotensin II in Follitropin Receptor Knockout Mice, a Model of Menopause-Associated Hypertension
Javeshghani et al.
Hypertension 2003;42:761-767.
ABSTRACT | FULL TEXT  

Ablation of PLB exacerbates ischemic injury to a lesser extent in female than male mice: protective role of NO
Cross et al.
Am. J. Physiol. Heart Circ. Physiol. 2003;284:H683-H690.
ABSTRACT | FULL TEXT  

Hormone Replacement Therapy and Associated Risk of Stroke in Postmenopausal Women
Lemaitre et al.
Arch Intern Med 2002;162:1954-1960.
ABSTRACT | FULL TEXT  

Postmenopausal Hormone Replacement Therapy: Scientific Review
Nelson et al.
JAMA 2002;288:872-881.
ABSTRACT | FULL TEXT  

Postmenopausal Hormone Replacement Therapy and the Primary Prevention of Cardiovascular Disease
Humphrey et al.
ANN INTERN MED 2002;137:273-284.
ABSTRACT | FULL TEXT  

Ca2+ loading and adrenergic stimulation reveal male/female differences in susceptibility to ischemia-reperfusion injury
Cross et al.
Am. J. Physiol. Heart Circ. Physiol. 2002;283:H481-H489.
ABSTRACT | FULL TEXT  

Male and female mice overexpressing the {beta}2-adrenergic receptor exhibit differences in ischemia/reperfusion injury: role of nitric oxide
Cross et al.
Cardiovasc Res 2002;53:662-671.
ABSTRACT | FULL TEXT  

Estrogenic hormone action in the heart: regulatory network and function
Babiker et al.
Cardiovasc Res 2002;53:709-719.
ABSTRACT | FULL TEXT  

Genome and Hormones: Gender Differences in Physiology: Selected Contribution: Estrogen receptor-alpha gene transfer inhibits proliferation and NF-kappa B activation in VSM cells from female rats
Sharma et al.
J. Appl. Physiol. 2001;91:2400-2406.
ABSTRACT | FULL TEXT  

Soy for Breast Cancer Survivors: A Critical Review of the Literature
Messina and Loprinzi
J. Nutr. 2001;131:3095S-3108.
ABSTRACT | FULL TEXT  

Risk of Recurrent Coronary Events in Relation to Use and Recent Initiation of Postmenopausal Hormone Therapy
Heckbert et al.
Arch Intern Med 2001;161:1709-1713.
ABSTRACT | FULL TEXT  

Endothelial Dysfunction and Oxidative Stress During Estrogen Deficiency in Spontaneously Hypertensive Rats
Wassmann et al.
Circulation 2001;103:435-441.
ABSTRACT | FULL TEXT  

A Prospective, Observational Study of Postmenopausal Hormone Therapy and Primary Prevention of Cardiovascular Disease
Grodstein et al.
ANN INTERN MED 2000;133:933-941.
ABSTRACT | FULL TEXT  

Differential Effects of Estrogen and Progesterone on AT1 Receptor Gene Expression in Vascular Smooth Muscle Cells
Nickenig et al.
Circulation 2000;102:1828-1833.
ABSTRACT | FULL TEXT  

Effect of 6-wk estrogen withdrawal or replacement on myocardial ischemic tolerance in rats
McNulty et al.
Am. J. Physiol. Heart Circ. Physiol. 2000;278:H1030-H1034.
ABSTRACT | FULL TEXT  

The Risk of Myocardial Infarction Associated with Inhaled beta -Adrenoceptor Agonists
AU et al.
Am. J. Respir. Crit. Care Med. 2000;161:827-830.
ABSTRACT | FULL TEXT  

Prescribing Hormone Replacement Therapy for Menopausal Symptoms
McNagny
ANN INTERN MED 1999;131:605-616.
ABSTRACT | FULL TEXT  

Hormone Replacement Therapy for Secondary Prevention of Coronary Heart Disease
Pan et al.
JAMA 1999;281:794-797.
FULL TEXT  

Hormone Replacement Therapy and Heart Disease Prevention: Experimentation Trumps Observation
Petitti
JAMA 1998;280:650-652.
FULL TEXT  

Estrogen Modulates AT1 Receptor Gene Expression In Vitro and In Vivo
Nickenig et al.
Circulation 1998;97:2197-2201.
ABSTRACT | FULL TEXT  

Estrogen: How Long Is Enough to Prevent MI?
JWatch Women's Health 1997;1997:5-5.
FULL TEXT  

Raloxifene Improves Endothelial Dysfunction in Hypertension by Reduced Oxidative Stress and Enhanced Nitric Oxide Production
Wassmann et al.
Circulation 2002;105:2083-2091.
ABSTRACT | FULL TEXT